Cost‐effectiveness of alternative interventions for the prevention and treatment of coronary heart disease
- 1 August 1995
- journal article
- review article
- Published by Wiley in Australian Journal of Public Health
- Vol. 19 (4) , 336-346
- https://doi.org/10.1111/j.1753-6405.1995.tb00384.x
Abstract
Although mortality from coronary heart disease (CHD) in Australia has fallen dramatically since the 1960s, it still remains the major cause of death in Australia and poses a significant burden on the economy. Even though a number of studies have concluded that prevention has been the main determinant of the declines in CHD, a disproportionate amount of health-care expenditure is devoted to treatment rather than prevention. This paper reviews the international literature on the economic appraisal (costs and benefits) of alternative interventions for the treatment and prevention of CHD with the view of assessing whether there is sufficient evidence to justify a reallocation of resources away from treatment to prevention. First, few studies on the economic evaluation of CHD prevention and treatment programs have been undertaken in Australia, with most being from the United States and Europe. Second, assumptions about the specification, measurement and valuation of costs, and the epidemiological evidence on program effectiveness have varied. Third, health promotion and prevention programs are not necessarily more cost-effective than drug or surgical treatments for CHD. Individual interventions must be judged on their own merits. There is a need for a systematic evaluation of interventions for CHD using primary Australian data to better inform decision making on resource-allocation priorities. Such an evaluation should incorporate economic evaluation techniques.Keywords
This publication has 54 references indexed in Scilit:
- Cost-effectiveness league tables: More harm than good?Social Science & Medicine, 1993
- Economic evaluation of cardiac rehabilitation soon after acute myocardial infarctionThe American Journal of Cardiology, 1993
- A health-economic comparison of diet and drug treatment in obese men with mild hypertensionJournal Of Hypertension, 1992
- Pharmacoeconomic Evaluation of Risk Factors for Cardiovascular DiseasePharmacoEconomics, 1992
- Costs and benefits of risk factor reduction for coronary heart disease: Insights from screening and treatment of serum cholesterolAmerican Heart Journal, 1990
- Primary Prevention of Coronary Heart Disease in the Federal Republic of GermanyDrugs, 1990
- The costs of treatment of hypertension in Switzerland and WorldwideCardiovascular Drugs and Therapy, 1989
- Costs and Effectiveness of Routine Therapy with Long-Term Beta-Adrenergic Antagonists after Acute Myocardial InfarctionNew England Journal of Medicine, 1988
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- EFFECT OF DIET AND SMOKING INTERVENTION ON THE INCIDENCE OF CORONARY HEART DISEASEThe Lancet, 1981